Company
Tubulis
Generates uniquely matched antibody-drug conjugates with durable on-tumor delivery in preclinical models.
Also known as Tubulis GmbH
- Status
- Acquiredas of 2026-09-22Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Planegg-Martinsried, Germany
- Founded
- 2018
- Customers
- our partners
- Legal name
- Tubulis GmbH
- tubulis.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models.
About the company
- Status notes
- Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Products
- Other
- TUB-030
- Web
- TUB-030
- Other
- TUB-040
- Web
- TUB-040
Exit
- Acquisition
- 2026-04-07
Loading relationship preview